Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial

NCT05681884 is registered in ClinicalTrials.gov with Greater Houston Retina Research as lead sponsor.

NCT NCT05681884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Faricimab for Retinal Non-Perfusion Associated With Non-Proliferative Diabetic Retinopathy: The MAGIC Phase 2, Multi-Center, Open-Label, Randomized Controlled Trial
Lead sponsor
Greater Houston Retina Research
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2023
Completion date
February 26, 2026
Enrollment
179 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy